Skip to main content
Premium Trial:

Request an Annual Quote

DeCode's Q1 Revenue Falls 15 Percent as R&D Spending Slides and Loss Widens

NEW YORK (GenomeWeb News) — DeCode Genetics today said first-quarter revenues decreased 15 percent as R&D spending dropped 18 percent and losses rose 9 percent.
 
Total receipts for the three months ended March 31 fell to $8.6 million from $10.1 million year over year.
 
DeCode said it also had $11.6 million in deferred revenue at the close of the first quarter, which it will recognize over future periods.
 
R&D spending fell to $12.7 million from $15.5 million year over year.
 
The company said losses increased to $22.6 million from $20.7 million in the year-ago period.
 
CEO Kari Stefansson said the company said it plans to launch other diagnostic tests this year, and said the company’s results reflect its focus on “advancing and expanding our product pipeline, therapeutics and diagnostics.
 
DeCode said it had around $135.1 million in cash, cash equivalents, and investments as of March 31.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.